PMID- 32194547
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 11
DP  - 2020
TI  - Inhibition of Histone H3K27 Acetylation Orchestrates Interleukin-9-Mediated and 
      Plays an Anti-Inflammatory Role in Cisplatin-Induced Acute Kidney Injury.
PG  - 231
LID - 10.3389/fimmu.2020.00231 [doi]
LID - 231
AB  - Nephrotoxicity is a major side effect of cisplatin (CP)- and platinum-related 
      chemotherapy, and inflammation contributes to disease pathogenesis. Interleukin-9 
      (IL-9) is a pleiotropic cytokine associated with inflammation. Here, we 
      investigated the key role of IL-9 as a regulator of protective mechanisms in 
      CP-induced acute kidney injury (AKI). We observed that IL-9 was decreased not 
      only in a CP-induced AKI mouse model but also in THP-1 and RAW264.7 cell lines. 
      Seventy-two hours post-CP injection, renal dysfunction and tubule injury were 
      significantly attenuated in IL-9 overexpression adeno-associated virus 9 
      (AAV9)-treated mice. The levels of serum urea, serum creatinine, kidney injury 
      molecule-1 (KIM-1), and histological damage were partially diminished following 
      treatment with IL-9. The renoprotective effects of IL-9 may be attributed to the 
      regulation of cytokines, and we found that IL-9 acted on macrophages in a 
      regulatory manner, promoting an anti-inflammatory phenotype. Furthermore, IL-9 
      enhanced the suppression of macrophage-driven renal inflammation. Inhibition of 
      H3K27 acetylation orchestrated IL-9-mediated renoprotection in CP-induced AKI. 
      Thus, our findings indicate novel and potent anti-inflammatory properties of IL-9 
      that confer preservation of kidney function and structure in CP-induced AKI, 
      which may counteract kidney disease procession.
CI  - Copyright (c) 2020 Jiang, Yuan, Zhu, He, Ge, Tang, Xu, Hu, Huang and Ma.
FAU - Jiang, Wenjuan
AU  - Jiang W
AD  - Anhui Province Key Laboratory of Major Autoimmune Diseases, School of Pharmacy, 
      Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei, China.
FAU - Yuan, Xinrong
AU  - Yuan X
AD  - Xiangya School of Medicine, Central South University, Changsha, China.
FAU - Zhu, Hong
AU  - Zhu H
AD  - Anhui Province Key Laboratory of Major Autoimmune Diseases, School of Pharmacy, 
      Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei, China.
FAU - He, Changsheng
AU  - He C
AD  - Anhui Province Key Laboratory of Major Autoimmune Diseases, School of Pharmacy, 
      Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei, China.
FAU - Ge, Caiqiong
AU  - Ge C
AD  - Anhui Province Key Laboratory of Major Autoimmune Diseases, School of Pharmacy, 
      Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei, China.
FAU - Tang, Qing
AU  - Tang Q
AD  - Anhui Province Key Laboratory of Major Autoimmune Diseases, School of Pharmacy, 
      Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei, China.
FAU - Xu, Chuanting
AU  - Xu C
AD  - Anhui Province Key Laboratory of Major Autoimmune Diseases, School of Pharmacy, 
      Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei, China.
FAU - Hu, Bingfeng
AU  - Hu B
AD  - Anhui Province Key Laboratory of Major Autoimmune Diseases, School of Pharmacy, 
      Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei, China.
FAU - Huang, Cheng
AU  - Huang C
AD  - Anhui Province Key Laboratory of Major Autoimmune Diseases, School of Pharmacy, 
      Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei, China.
FAU - Ma, Taotao
AU  - Ma T
AD  - Anhui Province Key Laboratory of Major Autoimmune Diseases, School of Pharmacy, 
      Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei, China.
AD  - College of Pharmacy, Northeast Ohio Medical University, Rootstown, OH, United 
      States.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200303
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Culture Media, Conditioned)
RN  - 0 (Cytokines)
RN  - 0 (Histones)
RN  - 0 (Hydroxamic Acids)
RN  - 0 (IL9 protein, human)
RN  - 0 (Interleukin-9)
RN  - 0 (Recombinant Proteins)
RN  - 3X2S926L3Z (trichostatin A)
RN  - 614OI1Z5WI (Valproic Acid)
RN  - EC 3.5.1.98 (Hdac2 protein, mouse)
RN  - EC 3.5.1.98 (Histone Deacetylase 2)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Acetylation
MH  - Acute Kidney Injury/chemically induced/*prevention & control
MH  - Animals
MH  - Cell Line
MH  - Cisplatin/*toxicity
MH  - Culture Media, Conditioned/pharmacology
MH  - Cytokines/metabolism
MH  - Gene Expression/drug effects
MH  - Histone Code/*drug effects
MH  - Histone Deacetylase 2/antagonists & inhibitors
MH  - Histones/*metabolism
MH  - Humans
MH  - Hydroxamic Acids/pharmacology
MH  - Interleukin-9/biosynthesis/genetics/metabolism/*pharmacology
MH  - Kidney Tubules, Proximal/cytology
MH  - Macrophages/metabolism
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Models, Animal
MH  - Random Allocation
MH  - Recombinant Proteins/metabolism/pharmacology
MH  - Specific Pathogen-Free Organisms
MH  - Valproic Acid/pharmacology
PMC - PMC7062682
OTO - NOTNLM
OT  - H3K27Ac
OT  - acute kidney injury
OT  - cisplatin
OT  - inflammation
OT  - interleukin-9
OT  - macrophage
EDAT- 2020/03/21 06:00
MHDA- 2021/03/16 06:00
PMCR- 2020/01/01
CRDT- 2020/03/21 06:00
PHST- 2019/10/14 00:00 [received]
PHST- 2020/01/28 00:00 [accepted]
PHST- 2020/03/21 06:00 [entrez]
PHST- 2020/03/21 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2020.00231 [doi]
PST - epublish
SO  - Front Immunol. 2020 Mar 3;11:231. doi: 10.3389/fimmu.2020.00231. eCollection 
      2020.